上药“回家”

Shanghai Pharmaceutical Flagship sets sail

这是一场横跨沪港两地4家上市公司的重组。重组后，两家医药上市公司将被注销，一家上市公司医药资产将被清空——吸纳了三家上市公司医药资产，拥有研发、制造、分销、零售完备产业链的“新上药”横空出世。

This is a reorganization of four companies that are listed in either Shanghai or HongKong.On November 5th,Shanghai Industrial Investment Company and Shanghai Pharma Group completed the restructuring of their major investments in the pharmaceutical industry,a key step in A-share market. Three listed companies,namely Shanghai Pharma(600849.SH),Shanghai Industrial Pharmaceutical Investment(600607.SH). and Shanghai Zhongxi Pharmaceutical (600842.SH) all held meetings for their general shareholders,where the motion for the acquiring and merging of the latter two by the former was passed in absence of major shareholders by a large margin: 90%voted yes. Eleven days later,shareholders of Shanghai Pharma also passed a motion to acquire the pharmaceutical assets of the red-chip Shanghai Industrial Company (0363.HK). After reorganization,the new Shanghai Pharma is expected to have sales revenue of 2.72 billion US dollars in 2009, second only to the SOE Sinopharm,and thus will become the country's second largest pharmaceutical company.After ten years of dormancy Shanghai Pharma's flagship has set sail again.